Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 477

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 477
---
 December 2017. He received his B.A, M.Sc. in Cell and Gene Therapy for Diabetes and Ph.D. in Cell Therapy for Diabetes from Tel Aviv University, Israel. Uri Ben Or, Chief Financial Officer Mr.Uri BenOr has served as Kadimastem’s Chief Financial Officer since June 2022 and its controller since its inception in 2010. Uri Ben Or brings over twenty -fiveyears of broad experience in corporate finance, accounting, M&A transactions, and IPOs. He has significant expertise, including serving as chief executive officer, with public life science companies traded on the Nasdaq and TASE. Since June 2007, Uri has also served as the Chief Financial Officer of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), and since September 2022, as the Chief Financial Officer of Wind -Buzz(TASE:WNBZ -L). From January 2021 to June 2025, he served as the Chief Financial Officer of Cannible Foodtech Ltd. (CSE:PLCN). From March 2021 to February 2022, Uri Ben Or was the Chief Financial Officer of Nuvectis Pharma (NASDAQ: NVCT). From January 2018 to February 2022, Mr.Ben Or served as the Chief Financial Officer of Maayan Ventures Ltd. (TASE: MAYN). From October 2019 to January of 2020, Mr.Ben Or also served as the Chief Financial Officer of BiomX Inc. (NYSE American: PHGE). From October of 2001 to April 2014 he served as the Chief Financial Officer of Glycominds LLC. Mr.Ben -Orstarted his career as an Auditor at PwC Israel from May of 1997 until July of 1999. Mr.Ben -Orholds a B.A. degree in Business from the College of Management Academic Studies, Israel and an MBA from Bar -IlanUniversity, Israel. He is a Certified Public Accountant in Israel. Ariel Revel, MD, Director of Medical Affairs Professor Ariel Revel has served since January of 2020 as Kadimastem’s Medical Affairs Director. From January 2024, Professor Revel served as a Medical Doctor for Maccabi Health Care Service. Since April 2017, he has served as a Professor of Medicine at Tel Aviv University, a Visiting Professor at Oxford University in the UK from October 2008 to October 2009, and a Visiting Professor at Stanford University in California